General

Medicines for Ireland fear a cementing of status quo

Medicines for Ireland, the representative association for generic and biosimilar suppliers in Ireland, has expressed concern that a promised new National Biosimilar Policy will result in no meaningful change in terms of the current lack of competition in the Irish pharmaceutical sector, notwithstanding an ongoing Department of Health public consultation exercise on the issue.

The association went on to describe the State’s existing medicine pricing agreement with IPHA as ‘protectionist’ due to the fact that its terms, through an enforced price entry point, restricts competition in the medicine market, in particular for biosimilar over biologic medicines.

For verified healthcare professionals

Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.

Register for free Log in

Join the conversation

Comments are open to registered members. Log in or register to share your thoughts on this article.

Log in to comment Register for free